Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2007-07-17
2007-07-17
Brusca, John S. (Department: 1631)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S320100, C536S023720, C536S023500
Reexamination Certificate
active
10677727
ABSTRACT:
The present invention provides viral vectors that have been engineered to contain a synthetic promoter that controls at least one essential gene. The synthetic promoter is induced by a specific gene product not normally produced in the cells in which the viral vector is to be transferred. The vectors are propagated in producer or helper cells that express the inducing factor, thereby permitting the virus to replicate to high titer. The lack of the inducing factor in the target cells precludes viral replication, however, meaning that no vector toxicity or immunogenicity arises. Where the virus carries a gene of interest, this should provide for higher level expression for longer periods of time than with current vectors. Methods for making the vectors, helper cells, and their use in protein production, vaccines and gene therapy are disclosed.
REFERENCES:
patent: 5527676 (1996-06-01), Vogelstein et al.
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 6306652 (2001-10-01), Fallaux et al.
patent: 6630344 (2003-10-01), Fang et al.
patent: 6899870 (2005-05-01), McDonnell et al.
patent: 2729674 (1996-07-01), None
patent: WO 96/17053 (1996-06-01), None
Imler Adenovirus vectors as recombinant viral vaccines. Vaccine vol. 13 pp. 1143-1151 (1995).
Gilardi et al. The E4 promoter of adenovirus type 2 contains an E1A dependent cis-acting element. Nucleic Acids Res. vol. 14 pp. 9035-9049.
Abel et al., “DNA elements responsive to auxin,” (Review),Bioessays, 18(8):647-54, Aug. 1996.
Abel et al., “The PS-IAA4/5-like family of early auxin-inducible mRNAs inArabidopsis thaliana,” J. Mol. Biol., 251(4):533-49, Aug. 1995.
Adler et al., “UV irradiation and heat shock mediate JNK activationviaalternate pathways,”J. Biol.. Chem., 270(44):26071-26077, 1995.
Ali-Osman et al., “Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases α and β, and DNA ligase in cells of human malignant glioma following in vivo cisplatin therapy,”J. Cell. Biochem., 54:11-19, 1994.
Baker et al., “Suppression of human colorectal carcinoma cell growth by wild-type p53,”Science, 249:912-915, Aug. 1990.
Baverstock and Will, “Evidence of the dominance of direct excitation of DNA in the formation of strand breaks in cells following irradiation,”Int. J. Radiat. Biol., 55(4):563-568, 1989.
Berkner, “Development of adenovirus vectors for the expression of heterologous genes,”Biotechniques, 6:616-629, 1988.
Berkner et al., “Generation of adenovirus by transfection of plasmids,”Nucleic Acids Research, 11:6003-6020, 1983.
Bett et al., “An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3,”Medical Sciences, 91:8802-8806, 1994.
Bigner et al., “Cyogenetics of human brain tumors,”Cancer Genet Cytogenet, 47:141-154, 1990.
Bigner et al., “Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas,”J. Neuropathol.&Experimental Neurol., XL(3):201-229, May/Jun. 1981.
Brand and Perrimon, “Targeted gene expression as a means of altering cell fates and generating dominant phenotypes,”Development, 118:401-415, 1993.
Braselmann et al., “A selective transcription induction system for mammalian cells based on Gal4-estrogen receptor fusion proteins,”Proc. Natl. Acad. Sci. USA, 90:1657-1661, Mar. 1993.
Clarke et al., “Thymocyte apoptosis induced by p53-dependent and independent pathways,”Nature, 362:849-852, Apr. 1993.
Di Leonardo et al., “DNA damage triggers a prolonged p53-dependent G1arrest and long-term induction of Cip1 in normal human fibroblasts,”Genes&Dev., 8:2540-2551, 1994.
Donehower et al., “Deficiency ofp53accelerates mammary tumorigenesis inWnt-1transgenic mice and promotes chromosomal instability,”Genes and Development, 9:882-895, 1995.
El-Deiry et al., “WAF1, a potential mediator of p53 tumor suppression,”Cell, 75:817-825, Nov. 1993.
El-Deiry et al., “WAF1/CIP1is induced inp53-mediated G1arrest and apoptosis,”Cancer Research, 54:1169-1174, Mar. 1994.
Eliyahu et al., “p53—a potential suppressor gene?”J. Cell. Biochem., UCLA Symposia on Molecular and Cellular Biology, Abstract I030, Feb.-Mar. 1990.
Evans et al., “Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation,”Cancer Research, 54:1596-1603, Mar. 1994.
Fang, Koch and Roth, “Diminishing adenovirus gene expression and viral replication by promoter replacement,”J Virol., 71(6):4798-4803, 1997.
Fang, Koch and Roth, “Replacing adenoviral E4 promoter with GAL4/TATA dramatically reduces viral gene expression,”Cancer Gene Therapy, 3(6):S25, Abstract p. 54, 1996.
Fanjul et al., “A new class of retinoids with selective inhibition of AP-1 inhibits proliferation,”Nature, 372:107-111, Nov. 1994.
Fischer et al., “GAL4 activates transcription inDrosophila,” Nature, 332:853-856, Apr. 1988.
Fraval et al., “Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted fromMicrococcus luteus,” Mutation Research, 51:121-132, 1978.
Fujiwara et al., “Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-typep53gene,”Cancer Research, 54:2287-2291, May 1994.
Gipp et al., “DNA damage induced in HT-29 colon cancer cells by exposure to 1-methyl-2-nitrosoimidazole, a reductive metabolite of 1-methyl-2-nitroimidazole,”Biochem. Pharmacol., Suppl., 42:S127-S133, 1991.
Gjerset et al., “Use of wild-typep53to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53,”Mol. Carcinogenesis, 14:275-285, 1995.
Haj-Ahmad et al., “Development of a helper-independent human andenovirus vector and its use in the transfer of the herpes simplex thymiding kinase gene,”Journal of Virology, 57:267-274, 1986.
Hayashi et al., “Expression of a thyroid hormone-responsive recombinant gene introduced into adult mice livers by replication defective adenovirus can be regulated by endogenous thyroid hormone receptor,”Journal of Biological Chemistry, 269:23872-2375, 1994.
Hinds, “Biological consequences of mutation of the p53 proto-oncogene,” a dissertation presented to the faculty of Princeton University in candidacy for the degree of Doctor of Philosophy, Oct. 1989.
International Search Report dated Apr. 20, 1998 (PCT/US97/20608)(INGN:033P).
Izumoto et al., “Homozygous deletions of p16INK4A/MTS1 and p15INK4B/MTS2 genes in glioma cells and primary glioma tissues,”Cancer Letters, 97:241-247, 1995.
Jen et al., “Deletion ofp16andp15genes in brain tumors,”Cancer Research, 54:6353-6358, Dec. 1994.
Kaden et al., “High frequency of large spontaneous deletions of DNA in tumor-derived CHEF cells,”Proc. Natl. Acad. Sci. USA, 86:2306-2310, Apr. 1989.
Kamb, “Cell-cycle regulators and cancer,”TIG, 11(4):136-140, Apr. 1995.
Kashani-Sabet et al., “Cyclosporin A suppresses cisplatin-induced c-fosgene expression in ovarian carcinoma cells,”J. Biol. Chem., 265(19):11285-11288, Jul. 1990.
Kashani-Sabet et al., “Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil,”Eur. J. Cancer, 26(3):383-390, 1990.
Kimler, “The 9L rat brain tumor model for pre-clinical investigation of radiation-chemotherapy interactions,”J. Neuro-Oncology, 20:103-109, 1994.
Krougliak and Graham, “Development of cell lines capable of complementin
Fang Bingliang
Roth Jack A.
Brusca John S.
Fulbright & Jaworski L.L.P.
The Board of Regents of the University of Texas System
LandOfFree
Diminishing viral gene expression by promoter replacement does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diminishing viral gene expression by promoter replacement, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diminishing viral gene expression by promoter replacement will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3742968